Catalent, Inc. (NYSE:CTLT) Short Interest Up 22.5% in July

Catalent, Inc. (NYSE:CTLT) saw a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 10,550,000 shares, an increase of 22.5% from the June 30th total of 8,610,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the short-interest ratio is currently 6.1 days.

Catalent Trading Up 0.1 %

Shares of CTLT stock traded up $0.06 on Tuesday, hitting $59.04. 2,095,975 shares of the company’s stock traded hands, compared to its average volume of 2,204,608. The stock has a market capitalization of $10.69 billion, a price-to-earnings ratio of -9.68, a P/E/G ratio of 2.42 and a beta of 1.16. The company’s fifty day simple moving average is $56.29 and its 200 day simple moving average is $55.84. Catalent has a one year low of $31.80 and a one year high of $60.20. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. Equities analysts forecast that Catalent will post -0.17 EPS for the current year.

Insider Buying and Selling

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ricky Hopson sold 1,401 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,482 shares of company stock valued at $779,852. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Large investors have recently bought and sold shares of the stock. Lindbrook Capital LLC boosted its stake in shares of Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares during the period. GAMMA Investing LLC purchased a new stake in Catalent during the 4th quarter valued at $33,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalent in the second quarter valued at about $42,000. Rakuten Securities Inc. purchased a new position in shares of Catalent in the fourth quarter valued at about $46,000. Finally, Federated Hermes Inc. bought a new position in shares of Catalent during the fourth quarter valued at about $46,000.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CTLT. StockNews.com assumed coverage on Catalent in a research note on Wednesday, July 24th. They issued a “sell” rating on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Stephens reissued an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Finally, Barclays raised their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $55.65.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.